Standard first-line chemotherapy with or without nintedanib for advanced ovarian cancer (AGO-OVAR 12): a randomised, double-blind, placebo-controlled phase 3 trial.

Saved in:
Bibliographic Details
Title: Standard first-line chemotherapy with or without nintedanib for advanced ovarian cancer (AGO-OVAR 12): a randomised, double-blind, placebo-controlled phase 3 trial.
Authors: du Bois A; Kliniken Essen Mitte, Essen, Germany. Electronic address: prof.dubois@googlemail.com., Kristensen G; Department of Gynecologic Oncology and Institute for Cancer Genetics and Informatics, Oslo University Hospital, and Oslo University, Oslo, Norway., Ray-Coquard I; Centre Leon Berard and University of Lyon, Lyon, France., Reuss A; Coordinating Center for Clinical Trials, Marburg, Germany., Pignata S; National Cancer Institute of Naples, Naples, Italy., Colombo N; University of Milan Bicocca, Milan, Italy; European Institute of Oncology Milan, Milan, Italy., Denison U; Health + Life Gesundheitsmanagement GmbH, Vienna, Austria., Vergote I; University Hospitals Leuven, Leuven, Belgium., Del Campo JM; Vall d'Hebron University Hospital Barcelona, Barcelona, Spain., Ottevanger P; UMC St Radboud Nijmegen, Nijmegen, Netherlands., Heubner M; West German Tumor Center, Department of Gynecology and Obstetrics, University of Duisburg-Essen, Essen, Germany., Minarik T; National Institute of Oncology, Bratislava, Slovakia., Sevin E; Centre François Baclesse, Comité Uro-Gynécologie, Caen, France., de Gregorio N; Department of Gynecology, University Hospital, Ulm, Germany., Bidziński M; Faculty of Health Science, University of Jan Kochanowski, Kielce, Poland., Pfisterer J; Gynecologic Oncology Center, Kiel, Germany., Malander S; University Hospital, Department of Oncology, Lund, Sweden., Hilpert F; Universitäts-Klinik Schleswig-Holstein (UKSH) Campus Kiel, Department of Gynecology and Obstetrics, Kiel, Germany., Mirza MR; Rigshospitalet-Copenhagen University Hospital, Department of Oncology, Copenhagen, Denmark., Scambia G; Universita Cattolica del Sacro Cuore Policlinico Gemelli, Rome, Italy., Meier W; Evangelisches Krankenhaus, Department of Gynecology and Obstetrics, Duesseldorf, Germany., Nicoletto MO; Istituto Oncologico Veneto Istituto di Ricovero e Cura a Carattere Scientifico (IRCSS), Oncologia MedicaI, Padova, Italy., Bjørge L; Haukeland Universitetssykehus, Bergen, Norway., Lortholary A; Centre Catherine de Sienne, Nantes, France., Sailer MO; Boehringer Ingelheim, Ingelheim, Germany., Merger M; Boehringer Ingelheim, Ingelheim, Germany., Harter P; Kliniken Essen Mitte, Essen, Germany.
Corporate Authors: AGO Study Group led Gynecologic Cancer Intergroup/European Network of Gynaecologic Oncology Trials Groups Intergroup Consortium
Source: The Lancet. Oncology [Lancet Oncol] 2016 Jan; Vol. 17 (1), pp. 78-89. Date of Electronic Publication: 2015 Nov 16.
Publication Type: Clinical Trial, Phase III; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
Journal Info: Publisher: Lancet Pub. Group Country of Publication: England NLM ID: 100957246 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1474-5488 (Electronic) Linking ISSN: 14702045 NLM ISO Abbreviation: Lancet Oncol Subsets: MEDLINE
Database: MEDLINE Ultimate
Description
ISSN:1474-5488
DOI:10.1016/S1470-2045(15)00366-6